Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Post-transplant lymphoproliferative disease

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma A Study of the Safety and Efficacy of EBV Specific T-cell Lines Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Early Detection of Epstein-Barr Virus Related Disease. Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD) Cellular Immunotherapy for Viral Induced Cancer – EBV Positive Lymphomas Bortezomib Plus Rituximab for EBV+ PTLD Risk Stratified Sequential Treatment for CD20-positive PTLD Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD) Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy